The ACS Ethnicity Platelet Function Study
Recruitment status was: Recruiting
This study is being done to assess the effects of the CTP inhibitor on the function of your platelets (cells within your blood that are involved in the formation of blood clots) and to assess whether you have responded to the ticagrelor well enough to prevent the formation of blood clots within the stent or site in which angioplasty was performed.
Recent studies have looked at how racial differences can affect platelet reactivity, the way blood clots. But these studies have not looked at the way different racial backgrounds can affect the way the blood forms clots. Minorities, such as African-Americans are underrepresented. Therefore, we are conducting this platelet reactivity study to better understand if there are differences in how this drug affects African-Americans from how they affect Caucasian patients undergoing percutaneous coronary intervention and receiving ticagrelor. These data will be compared to a historical control of Caucasian patients who underwent similar platelet function testing.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The ACS Ethnicity Platelet Function Study|
- Ticagrelor Inhibition [ Time Frame: 1-2 days ] [ Designated as safety issue: No ]The primary objective of the study is to assess ticagrelor's inhibition of platelet activity using 3 assays simultaneously: VerifyNow P2Y12 (PRU), vasodilator-stimulated phosphoprotein phosphorylation (VASP) and light transmission aggregometry (LTA) in African-American patients presenting with ACS.
- Follow-up Adverse Events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]To evaluate the safety of ticagrelor treatment in African-American patients by assessment of adverse-events up to 30-day follow-up time point.
|Study Start Date:||May 2013|
|Estimated Primary Completion Date:||February 2015 (Final data collection date for primary outcome measure)|
African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01829659
|United States, District of Columbia|
|Medstar Washington Hospital Center|
|Washington, District of Columbia, United States, 20010|
|Principal Investigator:||Ron Waksman, MD||Medstar Washington Hospital Center|